ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Roche builds multiple sclerosis portfolio

by Lisa M. Jarvis
April 9, 2018 | APPEARED IN VOLUME 96, ISSUE 15

Roche has paid an undisclosed sum for a multiple sclerosis drug program developed by Inception 5, a biotech firm formed in 2014 with funding from Roche and Versant Ventures. Inception 5 is based on a University of California, San Francisco, technology for finding small molecules that can repair damaged nerve fibers. It’s one of several build-to-buy companies to emerge from Versant’s drug discovery incubator, Inception Sciences. Versant has now committed $25 million to Pipeline Therapeutics, a new company from the Inception 5 team that’s focused on neuroregeneration.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment